Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus PRAVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus PRAVASTATIN SODIUM.
BAYCOL vs PRAVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Lowers LDL cholesterol, triglycerides, and increases HDL cholesterol by upregulating hepatic LDL receptor expression.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
10-40 mg orally once daily; initiate at 10-20 mg and titrate based on response.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Terminal elimination half-life is 1.3-2.6 hours; despite short half-life, HMG-CoA reductase inhibition persists longer due to effective hepatic extraction and enterohepatic recirculation.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Primarily biliary (60% as unchanged drug and metabolites), with approximately 20% renal excretion; fecal elimination accounts for about 70% of total clearance.
Category C
Category D/X
Statin
Statin